CING Cingulate
- 0.7909
- +0.0299+3.93%
- 0.7801
- -0.0108-1.37%
Cingulate News
Analysts Conflicted on These Healthcare Names: Cingulate Inc (CING) and Genenta Science SpA Sponsored ADR (GNTA)
As Of March 31, 2024, Cingulate Had $1.1M In Cash And Cash Equivalents. Management Intends To Seek Opportunities To Access Additional Capital As Needed
As Of March 31, 2024, Cingulate Had $1.1M In Cash And Cash Equivalents. Management Intends To Seek Opportunities To Access Additional Capital As Needed
Cingulate Q4 2023 GAAP EPS $(0.60) May Not Be Comparable To $(4.86) Estimate
Cingulate Q4 2023 GAAP EPS $(0.60) May Not Be Comparable To $(4.86) Estimate
10-Q: Quarterly report
Cingulate 1Q Loss/Shr 60c >CINGW
Cingulate 1Q Loss/Shr 60c >CINGW
Press Release: Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update CTx-1301 on track to file for Marketing Approval with FDA in 1H 2025 Increase of $10 Million in Stock
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
CTx-1301 on track to file for Marketing Approval with FDA in 1H 2025 Increase of $10 Million in Stockholders' Equity KANSAS CITY, Kan., May 08, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to Be Featured With Chairman and CEO Shane J. Schaffer on Benzinga All Live Access
KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Cingulate Inc (CING) Receives a Hold From Maxim Group
Cingulate Reports Q4 Results
Cingulate Had $52,416 in Cash and Cash Equivalent at Dec 31 >CINGW
Cingulate Had $52,416 in Cash and Cash Equivalent at Dec 31 >CINGW
Cingulate 4Q Loss $6.93M >CINGW
Cingulate 4Q Loss $6.93M >CINGW
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the twelve months ended December 31, 2023, and provided a clinical and business update.
Cingulate to Participate in Benzinga All Live Access Event
Cingulate to Attend DCAT Week 2024 in New York City
KANSAS CITY, Kan., March 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Cingulate Inc Bolsters Board, Targets Nasdaq Compliance
Cingulate Expands Board With New Directors Amid Financial Activity Surge
Press Release: Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to Its Board of Directors
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors Announcement Follows Recent Public Offering and Successful Capital Raising Activity KANSAS CITY, Kan., Feb. 1
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersThermoGenesis Holdings (NASDAQ:THMO) stock moved upwards by 39.0% to $0.86 during Wednesday's regular session. The market value of their outstanding shares is at $2.7 million. Femasys (NASDAQ:F
Analysis
Price Target
No Data
